Skip to main content
Innate Pharma logo

Innate Pharma — Investor Relations & Filings

Ticker · IPH ISIN · FR0010331421 LEI · 9695002Y8420ZB8HJE29 PA Manufacturing
Open in API
Filings indexed 1,403 across all filing types
Latest filing 2024-06-04 Foreign Filer Report
Country FR France
Listing PA IPH

About Innate Pharma

http://www.innate-pharma.com/

Innate Pharma is a clinical-stage, oncology-focused biotechnology company that develops immunotherapies for cancer patients. The company's scientific approach is centered on leveraging the innate immune system, particularly Natural Killer (NK) cells, to create novel treatments. Its innovative pipeline is composed of antibody-based therapeutics, including first-in-class monoclonal antibodies, antibody-drug conjugates (ADCs), and multi-specific NK cell engagers based on its proprietary ANKET® platform. Key clinical programs include lacutamab (anti-KIR3DL2), monalizumab (anti-NKG2A) in partnership with AstraZeneca, and a portfolio of NK cell engagers targeting various hematological malignancies and solid tumors.

Recent filings

Filing Released Lang Actions
6-K
Foreign Filer Report
2024-06-04 English
Informations privilégiées / Autres communiqués
Earnings Release Classification · 1% confidence The document is a press release dated June 4, 2024, announcing positive Phase 2 study results for the drug lacutamab in Mycosis Fungoides. It details clinical efficacy data (response rates, progression-free survival) and mentions the presentation of these results at the ASCO annual congress. It also includes details about an upcoming virtual conference call to discuss these results. This format—a formal announcement of periodic financial/clinical results, often accompanied by data tables and commentary from management/investigators, but not the full regulatory filing itself—is characteristic of an Earnings Release (ER) or a general announcement. Since this is specifically about clinical trial results and data presentation, it functions as a key update on company performance/pipeline progress, fitting best under the Earnings Release (ER) category, which covers initial announcements of periodical results (even if the 'period' here is a clinical milestone announcement rather than a fiscal quarter). It is not a full 10-K, an Audit Report (AR), or a simple Report Publication Announcement (RPA) as it contains substantial substantive data, not just a notice of publication. Given the context of presenting key data updates, ER is the most appropriate fit among the choices. FY 2024
2024-06-04 French
Inside Information / Other news releases
Earnings Release Classification · 1% confidence The document is a press release dated June 4, 2024, announcing 'favorable results from the Phase 2 TELLOMAK study with lacutamab in mycosis fungoides (MF)' which were presented at the ASCO 2024 Annual Meeting. It contains key efficacy data (ORR, PFS), quotes from management and investigators, and details about an upcoming virtual KOL event. This format—a concise announcement of recent financial/clinical performance highlights, often released before a full quarterly report—strongly aligns with the definition of an Earnings Release (ER). It is not a full Annual Report (10-K), a comprehensive Interim Report (IR), or a transcript (CT). Since it is announcing results, it is classified as ER. FY 2024
2024-06-04 English
6-K
Foreign Filer Report
2024-05-28 English
Inside Information / Other news releases
Regulatory Filings Classification · 1% confidence The document is a press release dated May 28, 2024, announcing that members of Innate Pharma's executive team are scheduled to participate in several upcoming investor conferences in June 2024. This type of announcement, which details participation in investor events (like the Jefferies Global Healthcare Conference or Goldman Sachs 45th Annual Global Healthcare Conference), is typically classified as an Investor Presentation or related communication, but none of the definitions perfectly match 'Conference Schedule Announcement'. However, the content is directly aimed at investors regarding future engagement opportunities. The closest fit among the provided options is 'Investor Presentation' (IP), as these announcements often precede or accompany investor outreach materials. Alternatively, since it is a general announcement about investor relations activities, it could fall under 'Regulatory Filings' (RNS) as a general disclosure, but 'IP' is more specific to the context of investor conferences. Given the focus on upcoming investor events, 'IP' (Investor Presentation) is the most appropriate classification for this type of forward-looking investor communication, even though it's an announcement *about* participation rather than the presentation itself. Since it is a specific announcement about investor engagement, and not a formal report (10-K, IR) or a management change (MANG), IP is the best fit.
2024-05-28 English
Informations privilégiées / Autres communiqués
Report Publication Announcement Classification · 1% confidence The document is a press release dated May 28, 2024, announcing that members of Innate Pharma's management team will be participating in several upcoming investor conferences (Jefferies Global Healthcare Conference, Goldman Sachs 45th Annual Global Healthcare Conference, etc.) in June 2024. This type of announcement, which details management's schedule for meeting with investors at industry events, is typically classified as an Investor Presentation or related communication, but given the specific options, it most closely aligns with providing information intended for investors regarding future engagement. Since it is not a formal presentation document (IP) but an announcement about participation in investor events, and it is not a regulatory filing (RNS) or a general earnings release (ER), the best fit among the provided codes is 'Investor Presentation' (IP) as it directly relates to investor outreach and scheduling, or potentially 'Regulatory Filing' (RNS) if it were a catch-all. However, the content is purely about investor meetings. In many databases, such announcements are grouped with investor relations materials. Given the options, 'IP' (Investor Presentation) is the closest thematic fit for management communicating their investor engagement schedule, although 'RNS' (Regulatory Filings) is a possibility if the database strictly reserves 'IP' for actual slide decks. Since the document is a formal announcement detailing management's schedule for investor conferences, it falls under investor relations communication. I will select 'IP' as the most relevant category for investor-facing scheduling announcements, though 'RNS' is a strong secondary candidate if the definition of 'IP' is strictly limited to slide decks.
2024-05-28 French

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.